– Total revenues of $881 million in the first quarter
– Jakafi® net product revenues of $572 million in Q1 24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of.
– Total revenues of $919 million in the third quarter
– Jakafi® net product revenues of $636 million in Q3 23, $1.9 billion YTD 2023, driven by growth in total patients across all.
Incyte (Nasdaq:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion that recommends granting marketing authorization for capmatinib (Tabrecta®) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymalepithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.